PATIENTS WHO CAN RECEIVE PFO OCCLUDERS
The Amplatzer™ PFO Occluder is indicated to reduce the risk of recurrent ischemic stroke in patients—predominantly between the ages of 18 and 60 years—who have had a cryptogenic stroke due to a presumed paradoxical embolism as determined by a neurologist and cardiologist following an evaluation to exclude known causes of ischemic stroke. To learn more about cryptogenic stroke, including the potential causes, please visit cryptogenicstroke.com.
Among patients with an ischemic stroke and patent foramen ovale (PFO), the Amplatzer PFO Occluder has demonstrated excellent safety and efficacy in reducing the risk of recurrent stroke.
PFO Closure to Ease Patient Anxiety
For patients who have experienced cryptogenic stroke, the thought of a recurrence can generate anxiety. For patients’ peace of mind, the importance of determining and delivering the most effective treatment cannot be overemphasized.
To learn more about PFO closure and read frequently asked questions from patients, please visit cryptogenicstroke.com.
MAT-2008366 v1.0 | Item approved for Global OUS use only.